Refine by
Retinal Vascular Diseases Articles & Analysis: This-Year
1 news found
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. “We’re delighted to welcome Leone as Chair of the ...
ByKalaris